Board of Directors
Robert Taub is a serial entrepreneur and investor in several pharmaceutical and medical device companies. He gained an MBA at INSEAD and held various general management and sales and marketing positions with Monsanto, Baxter Travenol Laboratories and the Revlon Health Care Group.
Mr. Taub later became an entrepreneur in the pharmaceutical and medical fields in the 1980's. Prior to Nyxoah he co-founded and co-managed Octapharma, a human plasma protein company for 12 years. He also founded and managed Omrix Biopharmaceuticals throughout a NASDAQ IPO followed by the acquisition by Johnson & Johnson. He was an early investor and chairman of Neuroderm, a Parkinson’s disease pharmaceutical company, throughout its IPO on NASDAQ and later sale to Mitsibushi-Tanabe.
Janke Dittmer is a General Partner at Gilde Healthcare, a transatlantic healthcare fund.
Prior to that, he was Venture General Manager and Head of Business Development & Strategy within Philips' Corporate Venturing unit in Healthcare. He led investments in medtech, diagnostics and digital health companies including Sapiens (acquired by Medtronic for $200m), served as Engagement Manager at McKinsey and co-founded a Nanotech company in the Silicon Valley.
Mr. Dittmer earned a PhD in Physics from University of Cambridge and Post-Doc in Nanotechnology at University of California, Berkeley.
Kevin Rakin is co-founder of HighCape Partners and brings more than 25 years of experience as an executive in the life sciences industry. He most recently served as President of Shire Regenerative Medicine. Prior to joining Shire, Mr. Rakin was the Chairman and Chief Executive Officer of Advanced BioHealing.
Previously, he was a Co-Founder, President and Chief Executive Officer of Genaissance Pharmaceuticals, Inc. Mr. Rakin received an MBA from Columbia University and undergraduate degrees from the University of Cape Town, South Africa.
Mr. Don Deyo is the CEO of Fempulse LLC involved in developing bioelectronic medicine therapies for women’s health concerns.
Prior to this, he served in executive leadership roles at Medtronic, Inc. Here, he was VP of Research & Development for Neuromodulation, VP of Product Development & Technology for Cardiac Rhythm Management and VP and General Manager for Medtronic Paceart. He also founded executive consultancy MedTech Execs, which provides strategic and operational services to medical device and pharmaceutical companies through global network of experienced executives.
Mr. Deyo holds a B.Sci. in Computer Engineering and an MBA.
Prof. Pierre Gianello was awarded as Doctor in Medicine, Surgery and Obstetrics at the Université Catholique de Louvain (UCL, Brussels, Belgium). He acquired his education in abdominal surgery at the Cliniques Universitaires Saint-Luc in Brussels and at the hospital de La Croix-Rousse de Lyon, France. He completed his post-doc training at the Massachusetts General Hospital, Harvard Medical School, Boston (USA) in the Transplant Biology Research Center managed by Prof. David Sachs. In 1997, he became head of the Laboratory of Experimental Surgery and Transplantation at University of Louvain (UCL) and in 2005, he obtained the title of full Professor at UCL. He was then elected Dean of Research from 2006 to 2009 and Vice-Rector from 2009 up to 2011. He is today the general coordinator of Research of the Health Sciences Sector at UCL, Brussels and Councilor of the vice-rector in the research and on the international stage at UCL, Brussels.
Professor Gianello has won about ten scientific prizes and is the author of more than 200 published manuscripts in peer reviewed scientific journals.
As Chief Technology Officer of Cochlear Limited since 2017, Mr. Janssen leads a team of over 500 highly qualified engineers and scientists who implement the R&D strategy.
This includes responsibility for identifying and developing cutting-edge technologies and commercial products. He joined Cochlear in 2000 as Head of the Cochlear Technology Centre in Belgium, having previously worked with Philips Electronics where he was involved in R&D in the fields of high-tech electronics and cochlear implants. He was promoted to Senior Vice President, Design and Development in 2005 and appointed Cochlear Chief Technology Officer in 2017 with added responsibility for Business Development.